Celsion Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
8,251.40
25,494.30
22,461.10
22,053.70
20,402.20
11,883.40
Depreciation, Depletion & Amortization
346.70
376.80
432.50
1,028.50
553.00
356.90
Other Funds
1,939.70
2,169.70
2,664.10
2,525.30
3,305.30
5,704.10
Funds from Operations
9,844.30
22,947.70
19,364.50
18,500.00
16,543.80
5,822.40
Changes in Working Capital
372.80
1,594.70
1,466.10
120.60
98.30
1,219.30
Net Operating Cash Flow
9,471.50
21,353.00
20,830.60
18,379.40
16,642.10
7,041.70
Capital Expenditures
57.50
672.30
109.30
62.50
38.60
Purchase/Sale of Investments
29,182.40
12,986.40
13,386.00
9,123.20
11,054.20
Net Investing Cash Flow
29,189.90
9,543.50
13,326.60
9,060.70
10,992.80
Issuance/Reduction of Debt, Net
296.90
4,989.10
3,654.20
4,099.80
2,595.90
Net Financing Cash Flow
29,388.50
18,777.90
4,082.20
2,677.70
36,454.80
Net Change in Cash
9,273.00
6,968.40
3,421.70
6,641.00
8,819.90
Free Cash Flow
9,529.00
22,025.30
20,939.90
18,441.90
16,680.70
Net Assets from Acquisitions
-
2,820.60
-
-
-
Other Sources
50.00
50.00
50.00
-
100.00
Change in Capital Stock
29,685.40
13,788.80
7,736.40
6,777.50
39,050.70

About Celsion

View Profile
Address
997 Lenox Drive
Lawrenceville New Jersey 08648
United States
Employees -
Website http://www.celsion.com
Updated 07/08/2019
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies.